Tango Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Tango Therapeutics, Inc. (TNGX) reported Capital Expenditures Incurred but Not yet Paid of $140.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-11
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was -$34.00K, a 1233.33% decline year-over-year.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was $248.00K.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-03-31 was $8.00K, a 88.73% decline year-over-year.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $3.00K.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $38.00K, a 70.99% decline from fiscal 2022.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $131.00K, a 14.94% decline from fiscal 2021.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $154.00K, a 431.03% increase from fiscal 2020.
- Tango Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $29.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $140.00K 10-Q · filed 2026-08-11 | |||
| 2025-09-30 | -$34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $214.00K derived: sum of 2 quarters · filed 2026-08-11 | $222.00K 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $256.00K 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | $8.00K 10-Q · filed 2026-05-13 | |||
| 2024-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$68.00K derived: sum of 2 quarters · filed 2025-11-04 | $3.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$71.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $71.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $38.00K 10-K · filed 2026-03-05 | |||
| 2023-03-31 | $290.00K 10-Q · filed 2024-05-08 | -$531.00K derived: sum of 2 quarters · filed 2025-02-27 | -$402.00K derived: sum of 3 quarters · filed 2025-02-27 | -$79.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$821.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$692.00K derived: sum of 2 quarters · filed 2025-02-27 | -$369.00K derived: sum of 3 quarters · filed 2025-02-27 | $131.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $452.00K derived: sum of 2 quarters · filed 2023-11-08 | $952.00K 10-Q · filed 2023-11-08 | $689.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $323.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $823.00K 10-Q · filed 2023-08-07 | $560.00K derived: sum of 3 quarters · filed 2023-08-07 | $324.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-09 | $237.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.00K derived: sum of 3 quarters · filed 2023-05-09 | $573.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$499.00K derived: sum of 2 quarters · filed 2023-03-27 | $73.00K derived: sum of 3 quarters · filed 2023-03-27 | $154.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | -$236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $336.00K derived: sum of 2 quarters · filed 2022-11-10 | $417.00K 10-Q · filed 2022-11-10 | $439.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $572.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $653.00K 10-Q · filed 2022-08-10 | $675.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $81.00K 10-Q · filed 2022-05-11 | $103.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $29.00K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $7.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |